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Abstract 
Background 
Opioid dependence, characterised by socio economic disadvantage and significant morbidity 
and mortality, remains a major public health problem in Ireland. Through the methadone 
treatment protocol (MTP), Irish general practice has been a leader in the introduction and 
expansion of Irish harm reduction services, including opioid substitution treatment (OST), 
needle and syringe programs (NSP) and naloxone provision. These services have been 
effective in engaging opiate users in treatment, reducing human deficiency virus (HIV) and 
hepatitis C virus (HCV) transmission and reducing drug related morbidities. Challenges 
remain in relation to choice of substitution treatments, timely access to OST services,  
adequate coverage of NSP, naloxone provision and increasing drug related deaths.  
Methods 
A narrative review was conducted and designed to present a broad perspective on the Irish 
MTP, and to describe its history and development in terms of clinical care, stakeholder views 
and changing trends. 
Results 
Three themes emerged from the analysis; The History of the Methadone Treatment Protocol, 
Service User and Provider Views, and Challenges and Developments. Despite initial concern 
about methadone maintenance treatment (MMT) in Ireland, increased participation by Irish 
GPs in the treatment of opioid dependence is observed over the last two decades. There are 
now over 10,000 people on methadone treatment in Ireland, with 40% treated in general 
practice. The MTP provides structure, remuneration and guidance to GPs and is underpinned 
by; training, ongoing education and a system of quality assurance provided by the Irish 
College of General Practice (ICGP). Challenges include the negative views of patients around 
how methadone services are delivered, the stigma associated with methadone treatment, the 
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lack of choice around substitution medication, waiting lists for treatment in certain areas and 
rates of fatal overdose. 
Conclusion 
Twenty years of the MTP has been the mainstay of harm reduction services in Ireland. It has 
provided a network of specially trained GPs who provide methadone to over 10,000 patients 
across Ireland within a structured framework of training, quality assurance and remuneration. 
With the ongoing commitment of Irish specialists in the field of addiction medicine, further 
improvements to support and treat patients can be made.  
 
Key Words; Ireland, general practice, methadone, opioid dependence, harm reduction 
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Background 
Opiate use in Ireland as elsewhere is characteristic of socio economic disadvantage, low 
educational attainment and restricted economic opportunity.1,2 The most recent capture re 
capture study of opiate users indicates that opiate use in Ireland is now entering a stabilised 
phase, with a small decrease in use compared to 2006 and the rate of use among young adults 
aged 15-24 years declining, and with a visible aging cohort effect of those in the 35 to 64 
years age group.3 In 2003, 6,667 individuals were registered on the Central Treatment List 
(CTL) out of 15,000 opiate users.4 Kelly, Carvalho and Teljeur5 estimated that in 2006 there 
were between 18,136 and 23,576 opioid users resident in Ireland, with the highest rate of 
heroin use in Europe at just over 7 cases per 1000 population, and small increases in the older 
drug using population and in Irish females. National prevalence and treatment data indicated 
at the time that opiate use was no longer confined to the greater urban context in the 
capital.1,5,6,7,8  
The overall number of cases treated for problem opiate use (mainly heroin) increased 
between 2006 and 2015.9 Most recent trends indicate a concerning shift towards greater 
levels of poly substance use5,6,9 with related treatment demand (i.e. benzodiazepines) since 
2007, dependence rates on over the counter and prescribed opiates such as codeine since 
2008,10 increase in drug related deaths,9 and the emergence of potent and potentially fatal 
synthetic fentanyls in 2018. Treatment data in 2013 reports that incidence of treated problem 
substance use among Travellers is three times that compared to the general population (523 
per hundred versus 173 per 100,000),11 with reports in 2017 indicating increased vulnerability 
of this ethnic minority to problem opiate use.9,12 In 2016, the Health Protection Surveillance 
Centre reported that the rate of infectious diseases (human immune deficiency virus, (HIV) 
and hepatitis C (HCV) is declining amongst people who inject drugs (PWID), despite an 
increase in 2015 due to a reported HIV outbreak.13  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
5 
 
In terms of pharmacological options to treat opiate dependence, substitution treatment 
using methadone is most common in Ireland, with buprenorphine-naloxone currently 
available on a limited basis.10 The Irish model of care for delivery of methadone treatment 
acknowledges the central role of the specialist trained general practitioner (GP) in primary 
care.14 The Irish College of General Practitioners (ICGP) has played a central role in 
developing the Methadone Treatment Protocol (MTP) which provided for the delivery of 
methadone treatment in primary care in the Irish context.  
A network of prescribing GPs work closely with statutory (funded and operated by 
the Health Services Executive, HSE) and non-statutory (part funded by the HSE through a 
service level agreement) organisations to optimise methadone treatment delivery. The 
network includes specialist GPs working in HSE addiction clinics and Level 1 and Level 2 
GPs working in primary care. Methadone treatment is commenced by specialist GPs in either 
addiction clinics or in a general practice setting (Level 2 GP).  Level 2 trained doctors are 
qualified to initiate treatment in general practice, stabilise doses and provide ongoing 
maintenance treatment.15 Level 1 trained doctors are encouraged to manage patients 
registered to their practice with patient stabilisation occurring in specialised clinics or with a 
Level 2 trained doctor. Once the patient is stabilised on methadone, referral to a Level 1 GPs 
working in the community for ongoing care is encouraged. All patients on methadone are 
listed on the confidential Central Treatment List (CTL) with each patient linked to one 
specific prescriber and a single dispensing site. Both Level 1 and Level 2 contracts attract 
additional remuneration for GPs caring for opioid dependent patients. Since 1998, greater 
prescribing of methadone in primary care has occurred, with the number of trained GPs rising 
steadily each year. There are currently (mid 2018) a total of 1718 trained Level 1 GPs and 
188 Level 2 trained GPs on the ICGP database. We present here a narrative review of the 
history and development of the Irish MTP, 20 years since its initial inception. 
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Methods 
A narrative review was conducted and designed to present a broad perspective on the Irish 
MTP, and describe its history and development in terms of clinical care, stakeholder views 
and changing trends. A comprehensive search was conducted on the National Documentation 
Centre for Drugs, Health Research Board database, with no restriction on date range or types 
of records.  Key search terms used were methadone treatment, general practice, opioid 
dependence and harm reduction combined with Ireland. Databases searched included 
PubMed, Science Direct, EMBASE, PsycINFO, Cochrane library and Medline. No limits 
were placed on dates. Follow up search strategies included hand searching relevant national 
websites including the Health Service Executive (HSE), Irish Prison Service (IPS), 
Departments of Health and Justice (DOH and DJ), the Irish Penal Reform Trust (IPRT), 
Health Surveillance Protection Centre (HSPC) and EMCDDA. A hand search of reference 
lists from published peer reviewed studies was also undertaken. References were managed by 
the citation manager Endnote®. National experts and authors of existing papers were 
contacted to identify possible sources of unpublished and grey literature. The research team 
reviewed the relevant literature and agreed on the structuring of the review under the 
following three themes; The History of the Methadone Treatment Protocol, Service User and 
Provider Views, and Challenges and Developments.  
 
The History of the Methadone Treatment Protocol (MTP) 
 
The Drug Treatment and Advisory Service was established in Jervis Street hospital in 1969. 
In 1971, methadone was introduced as the standardised therapeutic approach for treatment of 
opiate dependence, with physeptone treatment available to a small cohort of patients 
attending the service.  In 1979, the Jervis Street clinic in Dublin treated 55 heroin users; this 
figure rose to 213 in 1980.16 In the early 1980’s Dublin experienced what can be described as 
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‘an opiate epidemic’ For a 20 year period this was the only medical drug treatment facility in 
Dublin.17 In 1988, following the closure of the Jervis Street hospital, the drug treatment clinic 
was relocated to a central Dublin site named Trinity Court. In 1990, the newly established 
Dublin Drug Treatment Reporting System18 had 2037 opiate users treated in its expanding 
treatment system. Routine voluntary testing of drug users for HIV began in 1985 and over the 
first 2 years, 19% of those tested were diagnosed as being HIV positive. Needle and syringe 
provision was first provided in Ireland in 1989 in the former Eastern Health Board (EHB) 
AIDS Resource Centre in Dublin, in response to the heroin problem at the time.19 Methadone 
services, mainly focused on detoxification, have been available since 199220 and was initially 
restricted to the capital, Dublin.17 The ‘Report of the Expert Group on the Establishment of a 
Protocol for the Prescribing of Methadone’ was conducted in 199320. It recommended that 
services should be developed using this protocol to make methadone available free of charge 
and national in coverage to all persons undergoing methadone treatment for opiate 
dependence. It also included recommendations on the type and concentration of methadone to 
be used, the roles of general practitioners and pharmacists, and the relationships between 
treatment centres, general practitioners and pharmacists. The CTL for the prescribing of 
methadone was established in 1993, and by June 1997, 2232 people were registered as on 
methadone treatment. See Figure One, MTP Timeline.  
 
Insert Figure One ‘MTP Timeline’ about here 
 
The Methadone Treatment Services Review Group was set up by the Department of 
Health and Children in 1997 to assess methadone use in the treatment of heroin dependence. 
In 1998 the report of the Methadone Treatment Services Review Group was published 
(Methadone Treatment Services Review Group, 1998).21 In October 1998, legislation was 
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introduced as the ‘Misuse of Drugs (Supervision of Prescription and Supply of Methadone) 
Regulations’ which stipulated the regulatory structures for treating opioid dependent patients 
with methadone. It was also intended to encourage GPs to become involved in the treatment 
of drug dependence. The 1998 MTP was written to guide opioid dependent treatment delivery 
in primary care, with detailed protocols for methadone prescribing, guidance and standards 
for patient management and care, specialist training requirements for GPs, and protocols for 
clinical audit. As GPs were subsequently contractually required to have specific training if 
they wished to provide methadone treatment, the ICGP developed and delivered a number of 
training programmes to enable GPs to fulfil these contractual requirements: Level 1 GPs were 
provided with a daylong training programme while more experienced GPs who had been 
working with opiate dependent patients prior to the introduction of the protocol, were offered 
Level 2 status via a “grandfather clause”. Best practice guidelines, Working with Opiate 
Users in Community Based Primary Care were published by the ICGP22 and were issued to 
all GPs participating in the MTP. Ongoing audit formed part of the contractual obligations 
and the ICGP convened an audit review committee in conjunction with the EHB with the 
purpose of developing an audit process for GPs participating in the MTP. This Joint Audit 
Review Group (ARG) 23 developed a model of external audit of adherence to the MTP, which 
was the first of its kind in Irish general practice. In addition to overseeing the audit process, 
the ARG was given the remit of overseeing training and continuing medical education (CME) 
for GPs participating in the MTP delivered by the ICGP. The audit process underwent a 
number of changes since then and, since 2017, utilises a blended method of online self-audit 
supplemented by random external audit.24 The aim of this novel audit process is to assess the 
quality of care provided by GPs to patients on methadone maintenance treatment (MMT) so 
as to ensure that patient care meets national and international best practice standards. 
Furthermore, it aims to enhance practice based learning and reflective practice in order to 
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improve patient care and safety, minimise methadone diversion, reduce drug overdose rates, 
address associated health conditions and optimise patient rehabilitative outcomes within the 
practice.24 
Reviews of the MTP were conducted internally in 2005 by the ‘Methadone 
Prescribing Implementation Committee’ itself and externally in 2010.25 The 2010 review was 
an external review of the MTP undertaken to inform and maximise treatment provision and 
assess clinical governance and audit, referral pathways, doctor enrolment, training (Level 1 
and 2) and GP coordination.25 The review commented on improved prescribing and quality of 
independent practitioner practice, and advised the need to maximize treatment provision and 
referral pathways. It also commented on a number of other issues; timely responses to 
requests for detoxification to be reviewed as part of a service audit process, (see ‘National 
Drugs Rehabilitation Framework’ Working Group on Drugs Rehabilitation, 2007),26 rural 
service development, improved integration between and among services, improved clinical 
governance and audit, a need to review benzodiazepine prescribing (see ‘Report of the 
Benzodiazepine Committee’ Department of Health and Children 2002),27 changing urine 
analysis regimes, prescribing of methadone in police stations and the expansion of the 
number of Level 2 doctors with greater emphasis on transfer of patients from Level 2 to 
Level 1 doctors. Farrell and Barry25 also commented on the inclusion of buprenorphine and 
naloxone treatment modalities, and the need to revise the title to “The Opioid Treatment 
Protocol”.  See Table One and Figure Two.  
 
Insert Table One. ‘Number of patients on MMT , by year, CTL 2007-2017’ about here 
Insert Figure Two. ‘Number on MMT and new HIV Diagnosis related to IDU’ about 
here 
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Service User and Provider Views 
Early studies on Irish treatment provider experiences of methadone were mixed.28 Service 
users described negative aspects centring on the patient lack of choice, humiliating 
experiences in consuming methadone in a public space, difficulties complying with punitive 
contracts and urine screening, and engaging with uncaring service providers.29,30,31,32 Service 
user views were reported to centre on methadone as vital to initial stages of stabilisation, and 
that, due to the lack of alternatives to methadone, treatment regimens and patient experiences 
became restrictive and confining, and seen as the only solution representative of the 'one size 
fits all' phenomenon.32,33 A 2012 study highlighted the influence of the GP in supporting 
recovery.34 Studies conducted in 2013 with GPs and service stakeholders35,36 and in 2016 
indicated a generally positive attitude of prescribing GPs toward methadone treatment.14  
The outcomes of a national treatment and rehabilitation outcome study were reported 
in 2009 and showed high retention rates in treatment, high levels of completion of 
detoxification programs, significant reduction in all illicit drug use (heroin, cocaine, 
benzodiazepine, cannabis, and illicit methadone), reduction in criminal activity, improved 
physical and  health, reduction in risky drug taking behaviour and injecting drug use (IDU), 
improved uptake in training and employment and accommodation. Of note was that the 
incidence of non-fatal overdose remained constant.6,37 See Table Two and Figure Three. 
 
Insert Table Two ‘Number of deaths, by year, NDRDI 2004 to 2015’ here 
Insert Figure Three ‘Drug related deaths in Ireland 2004-2015 2004 to 2015’ here 
 
Challenges and Developments 
Complexities around methadone provision in Ireland in the initial years centred on negative 
attitudes toward drug users and differences of opinions around abstinence as an ultimate 
goal.38,39,40 The MTP is restricted to the medico-pharmacological treatment of stabilised drug 
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dependent patients, with minor reference to psychotherapeutic treatment (Kenny & O’ 
Carroll, 2012).41 The absence of a framework for the use of psychotherapeutic interventions 
is deemed by Kenny and O Carroll41 to warrant improvement.  
A number of non-statutory agencies have a national brief and have in recent years 
advocated for the expansion of treatment, the decriminalisation of drug use, and the setting up 
of drug consumption rooms. Many provide support and advocacy groups and a number of the 
larger agencies provide residential detoxification facilities.24 A need for a widespread 
increase of detoxification services at both community and residential levels continues, along 
with a strengthened focus on family member support, dual diagnosis and mental health. 
26,32,42,43,44,45,46,47,48,49,50,51
 
Regional treatment structures continue to struggle to meet the demand outside of the 
greater Dublin area, amid increasing drug related deaths where methadone is implicated 
particularly within poly substance use, and changes in type of opioid abuse.24,52 Irish studies 
have reported on the elevated risk of drug related mortality in methadone maintenance 
treatment during treatment initiation, transition, post drop out or discharge.53,54 Rates of 
benzodiazepine use implicated in over dose deaths are concerning for patients on 
methadone.54,55  Improved monitoring, risk assessment and methadone treatment retention 
strategies are needed to inform national drug overdose plans and overdose prevention.52,56  
Given the increased trend in problem drug use among ethnic groups, current Irish 
opioid substitution guidelines are mainstream and do not refer specifically to the cultural 
considerations of ethnic minorities such as the Traveller community.57 Given the 
complexities of methadone maintained patients in terms of multi morbidity and chronic 
illness, O’Toole, Hambly, Cox, O’ Shea and Darker58 recommended a more holistic approach 
to integrating MMT with general medical needs, the increased role of the GP Practice nurse, 
GP incentives to train in MMT, that any formal review of MMT GP remuneration should take 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
12 
 
into account the additional workload of taking care of MMT patients,  and the promotion of 
better record-keeping with regard to chronic diseases and virology. Roy, McCarthy,  Kiernan, 
McGorrian, Keenan,  Mahon, & Sweeney59 more recently have recommended an increased 
awareness of cardiac safety guidelines, including relevant clinical and family history, 
baseline, and trough dose ECG monitoring, should be incorporated into methadone 
maintenance therapy protocols. 
Several additional key developments have occurred. Enhanced multi sited data 
modelling will be utilised to track and monitor outcomes for policy makers, service providers 
and service users.60 Van Hout & McElrath61 have reported on the development of service user 
fora, designed to advocate and empower service users of MMT services in Ireland within the 
treatment care pathways and beyond. The National Poisons Information centre reported on 16 
paediatric admissions for methadone toxicity in children under four years old in the period 
2005-2014 and in response, a safe storage of methadone protocol has been rolled out 
nationally.62  With regard to choice, at the time of writing in August 2018, buprenorphine-
naloxone (Suboxone®) is prescribed to approximately 100 patients predominantly with 
codeine dependence or other opiate based medications and with very little general practice 
involvement. 
 
Discussion 
The MTP in Ireland represents a model of care which uses existing primary care resources for 
maximum benefit. As was the case in other jurisdictions, the drivers for devising the MTP in 
Ireland, included the emergence of HIV amongst intravenous drug users and the unregulated 
prescribing of methadone by untrained GPs and pharmacists.63,64 The lack of co-ordination 
around the delivery of services prior to the introduction of the MTP contributed to poor 
practices, increased risk for patients and the refusal of GPs and others to look after drug 
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users. Attitudes amongst health care professionals twenty years ago prior to the inception of 
the Irish MTP, were that the opioid dependent patient group were problematic, difficult to 
deal with and would create chaos in the surgery setting. Despite evidence to the contrary, 
there was also a large degree of scepticism amongst health care professionals about the 
benefits of methadone, particularly methadone maintenance as abstinence based treatments 
and models of care were the norm at the time. The development of a new model of care in the 
form of the MTP represented recognition of harm reduction as a treatment option and 
provided a regulated structure for delivering MMT services. It also provided a legitimate “opt 
out” for GPs who did not wish to participate in the MTP; GPs could choose not to participate 
in the required addiction training and were consequently not eligible to provide MMT. The 
rationale for empowering GPs to become involved in treating drug users emerged from the 
UK and wider European experience.65,66 A national retention in treatment study also 
supported the view that the treatment of patients in primary care was a protective factor for 
retention in treatment.67 
Official endorsement for the MTP from the ICGP as the professional body for GPs 
was crucial in making it acceptable for GPs to get involved in this work. Prior to the 
introduction of the MTP, some of the messages emanating from the professional body were 
urging caution about the safety aspects of GP involvement in provision of MMT. The design 
of the protocol and regulatory controls around delivery of services gave GPs a greater sense 
of professional assurances and satisfaction in delivering services to drug users in their own 
practice.14 GPs also played a key role in the delivery of services in specialist addiction centres 
with most of Health Services Executive (HSE) specialist services delivered by experienced 
Level 2 GPs. Current negotiations for a new general medical services (GMS) GP contract in 
Ireland include recommendations that all GPs should have completed the Level 1 training 
programme and be eligible to take a Level 1 contract. The ICGP continues to encourage all 
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GP training schemes to avail of the Foundation Training in Substance Misuse (Level 1 
training) which is available free of charge to all GP registrars and members of the ICGP.  
The evidence from patients on the MTP suggests that it has contributed significantly 
to the improved health and wellbeing of many drug using patients.6 One of the major 
achievements on the MTP over the past 20 years is the containment of HIV transmission 
among Irish people who inject drugs (PWID). At the time of the design and introduction of 
the MTP there was major concern around rates of HIV infection and AIDS among small 
communities in the Dublin Inner City.68  Over the past decade the rates of new infections 
have been modest and reflect the impact of the overall harm reduction strategy which 
combined the provision of OST and the development and expansion of NSP. The number of 
new HIV diagnoses amongst injecting drug users in Ireland more than halved over the period 
from 2004 to 2009, and only 12 new infections were notified in 2017 among PWID57 An 
unexpected increase in HIV notifications which occurred in 2015 were related to increased 
injecting use of new psychoactive substances (NSP) among homeless and chaotic PWID.69 
This highlights the need for vigilance and lack of complacency with regard to ongoing 
support of harm reduction services in Ireland.  
The success with Hepatitis C infection has not been so marked and there is a 
substantial sub population of current and former injectors who have chronic HCV related 
liver disease.70,71,72 The challenge of treating and managing such individuals with the new 
direct acting anti-retroviral (DAA) therapies will demand substantial medical resources 
including the transfer of HCV assessment and treatment into community addiction services 
and primary care.73,74 The need to scale up HCV treatment to levels where it provides for 
“treatment as prevention” will be a major challenge over the next decade.57,73,74,75 The 
provision of MMT in the Irish Prison Service (IPS) was of further benefit to the introduction 
of the MTP. Until treatment became more widespread and continuity of care could be 
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guaranteed on entry or exit from prison, opiate users who were serving sentences were 
offered detoxification only. This resulted in increased risk of HIV and Hepatitis C 
transmission as well as the increased risk of fatal overdose on release. Policy within the IPS 
reflected the benefits identified with OST and prisoners are now either commenced on OST 
where appropriate or continued on their existing treatment regime when incarcerated. Re-
engagement with their community-based OST treatment service is now an important risk 
management element of the prison discharge policy.76  
Despite the benefits of the MTP in Ireland over the past 20 years, significant 
challenges remain today. Access to treatment can be difficult specifically in areas outside of 
Dublin where waiting lists to access treatment continue to exist. It remains a concern that 
some PWID’s can wait long periods of time to access treatment which may reflect a rigidity 
within the existing protocol and how it is being interpreted in certain areas. The lack of 
choice in terms of which substitution medication is available is another constraint as 
buprenorphine based medication is currently available on a limited basis only. Lack of 
flexibility with regard to geographical location of treatment is a factor which can become a 
barrier to treatment access. In some rural areas patients may have long journeys to travel to 
access treatment and in areas where availability of public transport is an issue this can 
significantly influence both access and retention in treatment.24 
The single biggest challenge related to the MTP in Ireland today is the level of drug 
related deaths.52 The ICGP convened a working group to discuss strategies to minimise drug 
related deaths as far back as 2007 however77 drug overdose death rates have remained 
stubbornly high over the past decade with 224 people dying in 2015.78 Most of those who 
died were male and were in their late 30s. The mean age of victims in 2015 was 39 years, the 
highest ever recorded, mainly due to the increase in deaths in those aged 55 years or older 
compared with 2014. The reason for this increase is not yet known, although more than half 
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of deaths among those aged 55 years or older were among women. Opioids were most 
commonly associated with drug-induced deaths, although they were frequently found 
together with other psychoactive substances, such as alcohol and prescription medicines. 
Drug users not on OST are at greater risk from opioid and methadone related deaths.   The 
drug-induced mortality rate among adults (aged 15-64 years) in Ireland was 70 deaths per 
million in 2015, which is more than three times the most recent European average of 21.8 
deaths per million.  
 
Conclusion 
Recent trends suggest a stabilisation or reduction in Irish opioid dependence rates yet opioid 
use remains a major public health problem.  The MTP was put in place 20 years ago to enable 
the expansion of harm reduction services in Ireland in order to combat the high rates of HIV 
infections and the deaths associated with an increasing heroin epidemic in socially deprived 
areas of Dublin.  Its introduction was controversial with mixed support from politicians, 
policy makers and medical professionals.  The evidence based harm reduction model 
challenged the existing traditional abstinence model of addiction treatment. The MTP is 
effective in supporting the retention of patients in MMT, reducing HIV and HCV 
transmission and improving the health and social functioning of opioid users. Despite the 
successes of the MTP, many challenges remain, including; negative views of patients around 
how services are delivered, the stigma associated with methadone treatment, the lack of 
choice around substitution medication, waiting lists for treatment in certain areas  and the  
rates of fatal overdose.  The first twenty years has taken the Irish leaders in this field of 
medicine on a journey of improvement, advocacy and political lobbying in order to get the 
best possible services for patients in need of OST. 
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The ICGP has been a leader in the expansion of MMT services and has been 
instrumental in mainstreaming the care of this marginalised patient group in general practice. 
It has developed accessible training and has continuously made efforts to make substance 
misuse a mainstream issue in primary care rather than a niche area for a small number of 
GP’s. It has been instrumental in developing a quality assurance audit with an educational 
focus at its core. This structured framework of training and quality assurance along with 
increased remuneration, helped to allay the fears of many GPs who were reluctant to get 
involved in methadone treatment.  Today a network of specially trained GPs provides 
methadone to over 10,000 patients across Ireland. Reducing stigma and normalising OST in 
primary care is a challenge particularly in the context of ongoing criticisms of long term 
maintenance treatment.79,80,81 The MTP has provided a structure and support for GPs 
prepared to provide holistic care to drug users. As the range and type of substance misuse 
continues to evolve, GPs have a key role in identifying patients who may have a problem. 
Over the counter (OTC) codeine abuse as well as opiate analgesic dependency are a growing 
cause for concern and general practice is a less stigmatising environment to offer care.79 
Raising awareness and equipping GPs to meet the needs of their patients who may have 
substance use issues is of paramount importance if lives are to be saved. This area of 
medicine should no longer remain an ‘opt in’ option; it is time to ensure that every GP is 
adequately trained to service their patients.  
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Table One. ‘Number of patients on MMT by year, CTL 2007-2017’  
Year  
 
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Total 
numbers on 
MMT 
8537 8718 9047 9266 9251 9419 9655 9764 9940 10087 10316 
Numbers of 
MMT with 
GPs 
3047 3085 3199 3360 3477 3589 3812 3951 4097 4184 4220 
New HIV 
Cases related 
to IDU 
55 40 30 22 16 17 21 28 49 20 17 
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Table Two ‘Number of deaths, by year, NDRDI 2004 to 2015’  
Year 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015  
All Deaths  431 503 554 620 628 656 607 645 660 704 719 695 
Poisonings 266 301 326 387 386 373 339 377 356 400 364 348 
(N = 7,422)  
 
 
 
  
 Figure One ‘MTP Timeline’  
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 Figure Two. ‘Number on MMT and new HIV Diagnosis related to IDU’ 
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 Figure Three ‘Drug related deaths in Ireland 2004-2015 2004 to 2015’  
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